Effective transfer of interleukin-12 gene to solid tumors using a novel gene delivery system, poly [D,L-2,4-diaminobutyric acid]

Cancer Gene Therapy

Volumn 11, Issue 2, 2004, Pages 103-108

  Iwashita, Yukio ^a   Ogawa, Tadashi ^a   Goto, Shigeru ^a   Nakanishi, Masaru ^b   Goto, Takeshi ^b   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

^b HISAMITSU PHARMACEUTICAL CO INC   (Japan)

Author keywords

B16F10; Interleukin 12; Intratumoral delivery; Poly D,L 2,4 diaminobutyric acid

Indexed keywords

2,4 DIAMINOBUTYRIC ACID; INTERLEUKIN 12; LUCIFERASE; POLY(2,4 DIAMINOBUTYRIC ACID); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENE; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNOTHERAPY; INTERLEUKIN 12 GENE; LYMPHOCYTE ACTIVATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

AMINOBUTYRIC ACIDS; ANIMALS; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

ANIMALIA; MURINAE;

EID: 0942268833     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700669     Document Type: Article

References (24)

1. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
2. Hendrzak JA, Brunda MJ. Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest. 1995:72:619-637.
3. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type I and cytotoxic lymphocytes. Blood. 1994;84:4008-4027.
4. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143;1992:127-142.
5. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol. 1998;161:927-932.
6. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol. 1995;17:71-77.
7. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991;146:3074-3081.
8. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 178;1993:1223-1230.
9. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med. 181;1995:901-914.
10. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90;1997:2541-2548.
11. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
12. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7:1995-2002.
13. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
14. Dow SW, Elmslie RE, Fradkin LG, et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther. 1999;10:2961-2972.
15. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999;6:1867-1875.
16. Mendiratta SK, Quezada A, Matar M, et al. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther. 1999;6:833-839.
17. Maheshwari A, Mahato RI, McGregor J, et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol Ther. 2000;2:121-130.
18. Maheshwari A, Han S, Mahato RI, Kim SW. Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in antitumor activity. Gene Ther. 2002;9:1075-1084.
19. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CM VmIL-12 using water-soluble lipopolymers. Mol Ther. 2001;4:130-138.
20. Yamashita YI, Shimada M, Hasegawa H, et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res. 2001;61:1005-1012.
21. Cavallo F, Di Carlo E, Butera M, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin. Cancer Res. 1999;59:414-421.
22. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998;60:4457-4464.
23. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.
24. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 1997;57:2681-2686.